KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

被引：23
作者：
Zhang, Zining [1 ,2 ]
Zhang, Heng [1 ,2 ]
Liao, Xiang [1 ,2 ]
Tsai, Hsiang-i [1 ,2 ]
机构：
[1] Jiangsu Univ, Inst Med Imaging & Artificial Intelligence, Zhenjiang, Peoples R China
[2] Jiangsu Univ, Affiliated Hosp, Dept Med Imaging, Zhenjiang, Peoples R China
来源：
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2023年 / 11卷
基金：
中国国家自然科学基金;
关键词：
PDAC; KRAS mutation; phosphokinase; metabolic reprogramming; therapy resistance; poorer prognosis; MUTANT KRAS; GLUTAMINE-METABOLISM; MOUSE MODEL; CANCER; CELL; INHIBITOR; INITIATION; GLYCOLYSIS; KRAS(G12D); EFFICACY;
D O I：
10.3389/fcell.2023.1147676
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It has a poor response to conventional therapy and has an extremely poor 5-year survival rate. PDAC is driven by multiple oncogene mutations, with the highest mutation frequency being observed in KRAS. The KRAS protein, which binds to GTP, has phosphokinase activity, which further activates downstream effectors. KRAS mutation contributes to cancer cell proliferation, metabolic reprogramming, immune escape, and therapy resistance in PDAC, acting as a critical driver of the disease. Thus, KRAS mutation is positively associated with poorer prognosis in pancreatic cancer patients. This review focus on the KRAS mutation patterns in PDAC, and further emphases its role in signal transduction, metabolic reprogramming, therapy resistance and prognosis, hoping to provide KRAS target therapy strategies for PDAC.
引用
收藏
页数：16
相关论文
共 160 条
  • [61] KrasG12D and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas
    Izeradjene, Kamel
    Combs, Chelsea
    Best, Melissa
    Gopinathan, Aarthi
    Wagner, Amary
    Girady, William M.
    Deng, Chu-Xia
    Hruban, Ralph H.
    Adsay, N. Volkan
    Tuveson, David A.
    Hingorani, Sunil R.
    [J]. CANCER CELL, 2007, 11 (03) : 229 - 243
  • [62] FBW7 (F-box andWDRepeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
    Ji, Shunrong
    Qin, Yi
    Liang, Chen
    Huang, Run
    Shi, Si
    Liu, Jiang
    Jin, Kaizhou
    Liang, Dingkong
    Xu, Wenyan
    Zhang, Bo
    Liu, Liang
    Liu, Chen
    Xu, Jin
    Ni, Quanxing
    Chiao, Paul J.
    Li, Min
    Yu, Xianjun
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3950 - 3960
  • [63] Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression
    Jiang, Wang
    Li, Hao
    Liu, Xiyu
    Zhang, Jianping
    Zhang, Wuhu
    Li, Tianjiao
    Liu, Liang
    Yu, Xianjun
    [J]. THERANOSTICS, 2020, 10 (25): : 11507 - 11519
  • [64] Pancreatic stellate cells regulate branched-chain amino acid metabolism in pancreatic cancer
    Jiang, Wenna
    Qiao, Lu
    Han, Yawei
    Zhang, Aimin
    An, Haohua
    Xiao, Jiawei
    Ren, Li
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [65] Lipid raft protein flotillin-1 is important for the interaction between SOS1 and H-Ras/K-Ras, leading to Ras activation
    Jin, Hao
    Koh, Minsoo
    Lim, Hyesol
    Yong, Hae-Young
    Kim, Eun-Sook
    Kim, Sun Young
    Kim, Kyoungmee
    Jung, Joohee
    Ryu, Won-Ji
    Choi, Kang-Yell
    Moon, Aree
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (09) : 1933 - 1946
  • [66] Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma
    Ju, Huai-Qiang
    Ying, Haoqiang
    Tian, Tian
    Ling, Jianhua
    Fu, Jie
    Lu, Yu
    Wu, Min
    Yang, Lifeng
    Achreja, Abhinav
    Chen, Gang
    Zhuang, Zhuonan
    Wang, Huamin
    Nagrath, Deepak
    Yao, Jun
    Hung, Mien-Chie
    DePinho, Ronald A.
    Huang, Peng
    Xu, Rui-Hua
    Chiao, Paul J.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [67] Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations
    Kaushik, Aman Chandra
    Wang, Yan-Jing
    Wang, Xiangeng
    Wei, Dong-Qing
    [J]. BRIEFINGS IN BIOINFORMATICS, 2021, 22 (03)
  • [68] Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
    Kazi, Aslamuzzaman
    Chen, Liwei
    Xiang, Shengyan
    Vangipurapu, Rajanikanth
    Yang, Hua
    Beato, Francisca
    Fang, Bin
    Williams, Terence M.
    Husain, Kazim
    Underwood, Patrick
    Fleming, Jason B.
    Malafa, Mokenge
    Welsh, Eric A.
    Koomen, John
    Trevino, Jose
    Sebti, Said M.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (14) : 4012 - 4024
  • [69] Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
    Kemp, Samantha B.
    Cheng, Noah
    Markosyan, Nune
    Sor, Rina
    Kim, Il-Kyu
    Hallin, Jill
    Shoush, Jason
    Quinones, Liz
    Brown, Natalie V.
    Bassett, Jared B.
    Joshi, Nikhil
    Yuan, Salina
    Smith, Molly
    Vostrejs, William P.
    Perez-Vale, Kia Z.
    Kahn, Benjamin
    Mo, Feiyan
    Donahue, Timothy R.
    Radu, Caius G.
    Clendenin, Cynthia
    Christensen, James G.
    Vonderheide, Robert H.
    Stanger, Ben Z.
    [J]. CANCER DISCOVERY, 2023, 13 (02) : 298 - 311
  • [70] Yap/Taz promote the scavenging of extracellular nutrients through macropinocytosis
    King, Bryan
    Araki, Jingwen
    Palm, Wilhelm
    Thompson, Craig B.
    [J]. GENES & DEVELOPMENT, 2020, 34 (19-20) : 1345 - 1358
234567891011